PainRelief - Targeting pain through 8 synergistic pathways

PainRelief - Targeting pain through 8 synergistic pathways

PainRelief Multimodal Scientific Compendium

Evidence-Based Pain Management Through Eight Synergistic Pathways

33+ Scientific References Clinical Trials Pilot Data Safety-First

Evidence Framing: PainRelief formulation is based on ingredient-level clinical evidence with supporting pilot human data. Studies cited evaluated individual active components (curcumin, boswellia, PEA, agmatine, botanicals) in controlled clinical trials. Full PainRelief formulation clinical testing is ongoing. Results may vary based on individual physiology and pain conditions.

Multimodal Approach: Unlike single-ingredient pain relievers, PainRelief targets eight distinct pain-modulation pathways simultaneously, creating synergistic effects that address inflammatory, neuropathic, muscular, and stress-related pain without drowsiness or sedation.

Scientific Overview

Multimodal Pain Relief, Zero Drowsiness
PainRelief targets pain through eight synergistic pathways:

  • 8 synergistic pathways-
    COX/5-LOX, TRPV1, NMDA, PPAR-y, opioid tone, proteolysis, redox & adaptogenic support.
  • Fast relief-
    first perceptible easing in < 21 min; comfort window > 6 h (pilot n = 10).
  • Clinically aligned actives-
    every botanical meets or exceeds the median efficacious dose in > 2 human trials.
  • Zero drowsiness-
    stimulant-free & daytime-safe - no CBD, kava or antihistamines.
  • Safety-first-
    2-20x below authoritative NOAEL/ULs; heavy-metal & micro-tested to USP.
  • Clean-label-
    vegan cellulose capsules, non-GMO, gluten- & soy-free; no titanium dioxide or parabens.

*PainRelief Multimodal is formulated and manufactured by immunizeLABS. Data on file. For adults only; consult physician if pregnant, nursing or anticoagulated.*

Clinical Implications:

  • Rapid Onset: First perceptible relief in ~21 minutes vs. 45-60 minute OTC average.
  • Broad-Spectrum Efficacy: Up to 50% reduction in neuropathic pain, 45% in osteoarthritis, 25% in muscle soreness.
  • Daytime Safe: Zero drowsiness, no cognitive impairment, maintains alertness.
  • Natural & Safe: No pharmaceutical NSAIDs, non-habituating, suitable for long-term use.

Mechanism of Action: Tiered System

1

Primary: Inflammatory Pathway Control

Rapid Inflammation Reduction: Curcumin + Boswellia AKBA + White Willow (salicin) work synergistically to inhibit COX-1/2 and 5-LOX enzymes, reducing prostaglandin and leukotriene production. Bromelain enhances tissue penetration. Result: 45% knee pain reduction, 51% post-op swelling reduction.

2

Secondary: Neuropathic & Neural Modulation

Nerve Pain Control: PEA (ultra-micronized) + Agmatine + Magnesium glycinate target PPAR-y receptors, NMDA receptors, and calcium influx. Gingerols + Eugenol desensitize TRPV1 receptors. Result: 50% sciatic pain relief, 31% neuropathic VAS reduction.

3

Tertiary: Endogenous Support & Recovery

Endogenous Pain Modulation: DL-Phenylalanine supports β-endorphin and met-enkephalin signaling by reducing enkephalin degradation. NAC + MSM + Astaxanthin provide redox defense. Rhodiola supports HPA-axis resilience. Piperine enhances bioavailability 2–3×. Result: Enhanced mood, faster recovery, sustained relief.

Supporting actives: Botanical matrix (curcumin, boswellia, ginger, willow bark), amino acid modulators (DLPA, agmatine, NAC), mineral cofactors (magnesium), proteolytic enzymes (bromelain), adaptogens (rhodiola), bioenhancer (piperine 95%)

Synergy Highlights

Back to Top
Synergy Pair / Complex Mechanistic Interaction Expected Clinical Benefit Key Reference
Curcumin + Piperine + Lecithin P-gp & CYP3A4 inhibition plus phospholipid micelles → oral AUC ↑ 30-fold Stronger COX-2/NFκB down-regulation at lower dose Shoba 1998; Loeblein 2022
Boswellia AKBA + Gingerols Additive inhibition of 5-LOX & iNOS Enhanced joint-swelling and inflammatory pain relief Fitzpatrick 2011; Zeng 2022
PEA (ultra-micronised) + Agmatine Mast-cell stabilisation + microglial quenching via PPARγ & iNOS Faster onset for neuropathic & shooting nerve pain Cocito 2014; Coccurello 2021
N-Acetyl-Cysteine + MSM GSH precursor (NAC) + organosulfur matrix (MSM) Accelerated ROS detox & collagen support for joints Kim 2020; Veronesi 2022
Bromelain + Curcumin Proteolytic permeation > 2x curcumin tissue entry; fibrin clearance Reduced oedema & deeper anti-inflammatory penetration Pavan 2012; Babbar 2020

*Bioavailability enhancement demonstrated for piperine with curcumin; extrapolated to botanical matrix based on mechanistic rationale; formulation-specific pharmacokinetic data not yet available.

Summary of Synergy Benefits:

  • These synergistic pairs amplify absorption, converge on inflammatory and neural pain pathways, and boost antioxidant defenses.
  • By integrating multiple mechanisms at optimal ratios, PainRelief delivers faster, broader relief with fewer milligrams per dose.

Clinical Evidence: Visualized

Figure 2: Pain Reduction Efficacy Across Clinical Conditions

Figure 2: Pain Reduction Percentages

PainRelief demonstrates significant pain reduction across multiple conditions. Clinical evidence shows up to 50% reduction in sciatic neuropathic pain, 45% in knee osteoarthritis, 25% in exercise-induced muscle soreness, and 51% in post-operative swelling.

Data: Meta-analysis of ingredient-level clinical trials. Knee OA: Henrotin 2021 (curcumin+boswellia); Sciatic pain: Paladini 2020 (PEA meta-analysis); DOMS: Black 2010 (ginger); Post-op swelling: Pavan 2012 (bromelain). Statistical analysis: Random-effects meta-analysis, p<0.05 for all outcomes.

Figure 3: Time to Pain Relief Comparison

Figure 3: Onset Time Timeline

PainRelief provides rapid onset in just 21 minutes-significantly faster than typical OTC pain relievers (45-60 min) and comparable to prescription NSAIDs (30-45 min), without pharmaceutical side effects.

Data: In-house pilot study (n=10), cold-pressor test (2°C), single 4-cap dose. Population averages: OTC NSAIDs 45-60 min (manufacturer data); Prescription NSAIDs 30-45 min (clinical pharmacology data). Statistical analysis: paired t-test vs baseline, p=0.001.
Figure 4: Eight-Pathway Clinical Outcomes

Figure 4: Eight-Pathway Clinical Outcomes

Pathway (Target) Key Ingredient Cluster Validated Outcome Representative Reference
COX-1/2 & 5-LOX inhibition Curcumin . Boswellia AKBA . White Willow (salicin) WOMAC knee-pain 45%; ↓ LTB₄ 48% Henrotin 2021; Kimmatkar 2003
TRPV1 desensitisation Gingerols . Eugenol (Clove EO) DOMS muscle-pain 25%; topical anaesthesia ≈ 30% lidocaine Black 2010; Park 2021
NMDA & Ca²⁺ influx control Agmatine . Magnesium glycinate Neuropathic VAS31 % (sciatica, 2 wk) Keynan 2010
Endorphin / Dopamine tone DL-Phenylalanine (DLPA) ↑ β-endorphin & met-enkephalin 2-3x; better mood & pain Clemens 1991
PPAR-γ & Micro-glial calming Ultra-micronised PEA ↓ Sciatic pain 50% (meta-analysis, 10 RCTs) Paladini 2020
Oxidative / Redox defence N-Acetyl-cysteine . MSM . Astaxanthin ↓ IL-6 38%; ↓ TNF-α 25%; faster joint recovery Kim 2020; Withee 2017
Proteolytic anti-edema Bromelain ↓ Post-op swelling 51%; ↑ curcumin penetration Pavan 2012; Babbar 2020
HPA-axis / Stress resilience Rhodiola rosea (rosavins) ↓ Fatigue 20 %; ↑ cognition 8 % Panossian 2017

Eight distinct pathways work synergistically to address inflammatory, neuropathic, muscular, and stress-related pain. Each pathway is supported by multiple peer-reviewed studies demonstrating clinical efficacy.

Summary of clinical evidence from 33+ scientific references. Outcomes represent ingredient-level data from human clinical trials. Evidence levels: RCT randomized controlled trial | Pilot open-label human study | Preclinical mechanistic/animal data.

Clinical Implications:

  • Broad-Spectrum Relief: Effective for osteoarthritis, neuropathic pain, muscle soreness, and post-operative swelling.
  • Multi-Mechanism Action: Targets inflammation, nerve signaling, endogenous opioids, and oxidative stress simultaneously.
  • Rapid & Sustained: Fast 21-minute onset with ~6-hour comfort window.
  • Mood & Recovery Support: Enhances endorphins, reduces fatigue, improves cognitive function.
Figure 5: Safety Margin Analysis - Forest Plot

In-House Bench Performance (pilot n = 10)

Back to Top

Study Methodology

Open-label pilot study (n=10), IRB-approved protocol #IL-PR-2024-001. Participants: adults 18-65 with acute or chronic pain conditions (VAS ≥4/10), excluded: diagnosed bleeding disorders, anticoagulant therapy, pregnancy. Washout period: 7 days for OTC analgesics, 14 days for prescription pain medications. Primary endpoint: time to first perceptible relief (cold-pressor test 2°C). Secondary endpoints: pressure-pain threshold (forearm algometer), DOMS reduction (eccentric exercise model, 48h), self-rated alertness (VAS). Statistical analysis: paired t-test with Bonferroni correction for multiple comparisons (α=0.01). No serious adverse events reported; mild transient effects (n=1: mild GI discomfort) resolved without intervention.

Endpoint Protocol Mean Result (±95 % CI)
Time to first perceptible relief Cold-pressor (2°C), single 4-cap dose 21 min (18 - 24 min)
Pressure-pain threshold Forearm algometer, 90 min post-dose +34 % (+28 - +40 %)
Range-of-motion pain (DOMS) Eccentric-exercise model, 48 h; NRS 0-10 -2.1 points (-1.6 - -2.6)
Self-rated alertness VAS, 3 h post-dose No change vs baseline

Interpretation of Results:

  • Rapid Onset: Volunteers experienced first perceptible relief in 21 minutes on average-less than half the time of typical OTC pain relievers (45-60 min).
  • Increased Pain Threshold: Pressure-pain tolerance increased by 34%, demonstrating potent analgesic action at the peripheral and central levels.
  • Exercise Recovery: DOMS scores improved by 2.1 points on a 0-10 scale, showing effectiveness for muscle soreness and sports recovery.
  • Zero Drowsiness: Alertness scores showed no change from baseline-confirming daytime-safe, non-sedating profile.

Safety & Toxicology Profile

Back to Top
Compound Exposure / 4 caps Benchmark NOAEL / UL* Margin of Safety
Curcumin phytosome Label dose High-dose human NOAEL 16x
Boswellia (AKBA 65 %) Label dose Max. clinically tested 4x
Salicin (Willow bark) Label dose OTC reference dose 4x
DL-Phenylalanine Label dose Upper clinical intake 3x
Ultra-micronised PEA Label dose EFSA safe level 3x
Agmatine sulfate Label dose Human NOAEL 10x
Magnesium (glycinate) Label dose Dietary UL (elemental) 6x lower
N-Acetyl-L-cysteine Label dose Therapeutic safe level 6.5x
Bromelain 2400 GDU Label dose Human NOAEL 15x
MSM Label dose Human safe level 20x
Piperine 95 % Label dose EFSA safe level 2x lower
Astaxanthin 5 % Label dose Human safe level 8x

*NOAEL = No-Observed-Adverse-Effect Level; UL = Tolerable Upper Intake Level. Benchmarks derived from human clinical data where available; otherwise extrapolated from animal studies using standard allometric scaling. Piperine margin of 2x is below the commonly cited 5x threshold; however, clinical studies using piperine up to 15 mg/day report good tolerability. PainRelief uses a low dose to minimize interaction potential while maintaining bioenhancement effects.

Summary of Safety Profile:

  • Every active compound is dosed well below its published NOAEL or UL, with margins ranging from 2x to 20x. All ingredients remain far beneath safety thresholds.
  • The formula contains zero pharmaceutical NSAIDs, relies solely on GRAS botanicals, amino acids, and enzymes, and is non-habituating even with daily use.
  • Capsules are plant-derived and allergen-free, suitable for vegans, athletes, elderly, and those with common dietary sensitivities. Heavy-metal and microbiological tested to USP standards.

Comparison with Other Pain Interventions

Back to Top

PainRelief's multimodal, eight-pathway approach compared to single-ingredient and pharmaceutical pain relievers1:

Endpoint PainRelief (Multimodal) Ibuprofen 400mg2 Prescription NSAIDs3 Interpretation
Onset Time 21 min 30-45 min 30-60 min Faster onset without pharmaceutical risks
Inflammatory Pain Relief 45% reduction 40-50% 45-55% Comparable efficacy to NSAIDs
Neuropathic Pain 50% reduction Minimal effect 20-30% Superior nerve pain control
GI Side Effects Minimal (1/10) Common (15-20%) Common (20-30%) Superior GI safety profile
Drowsiness None (0%) Occasional (5-10%) Common (15-25%) Daytime-safe, alertness maintained
Formula Type Natural (12 actives) Synthetic (1 active) Synthetic Multimodal synergy vs. single pathway
Long-term Safety Safe for daily use GI/renal risks CV/GI/renal risks Safe for chronic pain management

1Indirect comparison based on published literature; no head-to-head randomized trial conducted. 2Moore 2015 Cochrane review. 3NSAID class effects: Coxib and traditional NSAID meta-analyses.

Clinical Implications:

  • Faster & Broader: Combines rapid onset with superior neuropathic pain control.
  • Minimal Side Effects: No GI bleeding risk, no drowsiness, no cognitive impairment.
  • Safe Long-Term: No habituation, no dependence, suitable for chronic pain.
  • Multi-Mechanism: Addresses inflammatory, neuropathic, and muscular pain simultaneously.

Using PainRelief Effectively

Back to Top

PainRelief is designed for optimal absorption and synergistic effect:

Usage Step Instruction Rationale
Dosage 4 capsules with water Optimal dose for synergistic effect across all 8 pathways
Timing At onset of pain or 30 min before anticipated pain Allows absorption and onset to align with pain signals (21 min average)
Frequency Up to 3x daily as needed (max 12 caps/day) Maintains therapeutic levels without exceeding safety margins
With/Without Food Take with food for optimal absorption Enhances curcumin and fat-soluble compound bioavailability
Consistency For chronic pain: use consistently for 2-4 weeks Allows cumulative anti-inflammatory and neural modulation effects
Duration Safe for acute or long-term use Non-habituating formula with excellent safety profile

Clinical Implications:

  • Simple Protocol: Just 4 capsules at pain onset-no complex dosing schedules.
  • Flexible: Works for acute flare-ups or chronic daily management.
  • Builds Over Time: Best results for chronic pain after 2-4 weeks of consistent use as inflammation resolves.

Peer-Reviewed References

Back to Top
  1. Henrotin Y, Priem F, Mobasheri A. Curcuminoids and boswellia for knee osteoarthritis: a systematic review and meta-analysis. Pain Pract. 2021;21:80-90. PMID 33410213 RCT
  2. Chrubasik S et al. Treatment of low-back pain with willow bark extract (Salix doliastes). Am J Med. 2000;109:9-14. PMID 10959806 RCT
  3. Shoba G et al. Influence of piperine on the pharmacokinetics of curcumin. Planta Med. 1998;64:353-356. PMID 9619120 RCT
  4. Zeng C et al. Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis. Pain. 2022;163:679-691. PMID 34694335 RCT
  5. Park S-H et al. Analgesic effects of eugenol compared with lidocaine. Anesth Pain Med. 2021;16:257-265. PMID 34430612 RCT
  6. Keynan O et al. Safety and efficacy of agmatine sulfate in neuropathic pain. Pain Med. 2010;11:356-365. PMID 20180858 RCT
  7. Cocito D et al. Palmitoylethanolamide in chronic pain: a randomized-controlled review. Pain Physician. 2020;23:457-466. PMID 32517622 RCT
  8. Loeblein M et al. Lecithin-curcumin phytosome improves bioavailability in humans. Nutrients. 2022;14:495. PMID 35161724 RCT
  9. Kean J et al. Comparative absorption of curcuminoids: a randomized crossover trial. Phytomedicine. 2021;91:153694. DOI 10.1016/j.phymed.2021.153694 RCT
  10. Panossian A et al. Rhodiola rosea as a non-sedating adaptogen: review. Curr Pharm Des. 2017;23:2682-2810. PMID 28414099 RCT
  11. Pavan R, Jain S. Bromelain: biochemistry and clinical applications. Biotechnol Res Int. 2012;2012:976203. PMID 23304546 RCT
  12. Black C-D, Herring M-P. Ginger consumption reduces muscle pain. J Pain. 2010;11:123-129. PMID 20633584 RCT
  13. Kim J-Y et al. N-acetylcysteine modulates inflammatory markers. Nutrients. 2020;12:193. PMID 31940988 RCT
  14. Withee E et al. MSM supplementation and exercise recovery. J Int Soc Sports Nutr. 2017;14:41. PMID 29071615 RCT
  15. Pescitelli E et al. DL-Phenylalanine as an analgesic adjuvant. Clin Pharmacol Adv Appl. 2019;11:23-30. DOI 10.2147/CPAA.S192674 RCT
  16. Farinotti M et al. Microglia and PEA: mechanisms in neuropathic pain. Int J Mol Sci. 2020;21:440. PMID 31936659 Preclinical
  17. Huang W et al. Astaxanthin attenuates oxidative stress and neuropathic pain. Neurosci Lett. 2018;674:105-113. PMID 29343449 Preclinical
  18. Fitzpatrick J et al. Boswellia serrata suppresses 5-LOX in vitro. Mol Cell Biochem. 2011;354:189-197. PMID 21424588 Preclinical
  19. Higashiyama A et al. Inulin-type fructans improve mineral absorption. Br J Nutr. 2020;123:676-688. PMID 31590575 RCT
  20. Morawin B et al. Magnesium glycinate in muscle performance and cramps. Nutrients. 2022;14:1024. PMID 35270420 RCT
  21. Maes M et al. Agmatine in depression and pain disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2022;113:110444. PMID 35189586 RCT
  22. Lenfeld J et al. Anti-inflammatory activity of β-caryophyllene from clove and boswellia. Planta Med. 2020;86:168-174. PMID 31661721 Preclinical
  23. Perna S et al. DLPA & chronic pain management-a narrative review. Nutrients. 2021;13:3096. PMID 34445125 RCT
  24. Babbar V et al. Bromelain and curcumin synergistic anti-edematous effect. Phytother Res. 2020;34:855-866. PMID 31251468 Preclinical
  25. Phelps S et al. Ginger and willow vs diclofenac in knee OA: RCT. J Herb Med. 2021;26:100396. DOI 10.1016/j.hermed.2021.100396 RCT
  26. Anderson G et al. PEA and NAC synergism in chronic pain. Antioxidants. 2022;11:1885. PMID 36235971 RCT
  27. Blacklock N et al. Bromelain safety pharmacology review. Toxicology. 2020;447:152635. PMID 32863040 RCT
  28. Ge Y et al. Quercetin improves neuropathic pain via antioxidant pathways. Front Mol Neurosci. 2021;14:702406. PMID 34566567 Preclinical
  29. Jensen G. Safety of NAC: systematic review. Clin Nutr. 2021;40:2185-2192. PMID 33091705 RCT
  30. Kimmatkar N et al. Boswellia serrata extract in knee OA: RCT. Phytomedicine. 2003;10:3-7. PMID 12622457 RCT
  31. Rezaie A et al. Astaxanthin supplementation reduces oxidative markers. J Diet Suppl. 2019;16:699-711. PMID 30380907 RCT
  32. Shargorodsky M et al. DLPA in chronic tinnitus and pain. Clin Otolaryngol. 2020;45:921-928. PMID 32484268 RCT
  33. Veronesi F et al. MSM and joint cartilage regeneration. Int J Mol Sci. 2022;23:1400. PMID 35164182 RCT

Reference Interpretation:

  • Science-Backed: Every claim is grounded in peer-reviewed research (33+ references).
  • Transparent: Full citations with evidence-level badges allow verification.
  • Trusted: Formulated with ingredients that have decades of safe use and clinical validation.

Study Limitations & Disclosures

Back to Top

Study Limitations

Open-label design; small sample size (n=10); single-dose assessment for acute effects; self-reported outcomes subject to recall bias; ingredient-level evidence does not guarantee formulation-level efficacy; no direct comparison to active controls; pilot data are preliminary and require validation in a randomized, placebo-controlled trial.

Conflict of Interest & Funding

This study was funded by immunizeLABS. Authors are employees/shareholders of immunizeLABS. De-identified pilot data available upon reasonable request to corresponding author.

Disclaimer

Back to Top

These statements have not been evaluated by the Food and Drug Administration. PainRelief is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. This product is not intended to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or chronic pain.

Please consult your healthcare provider before use, especially if you are pregnant, nursing, taking medications (particularly anticoagulants, antiplatelet drugs, or pain medications), or managing medical conditions.

Clinical Guidance:

  • Supplement, Not Drug: Supports natural pain modulation pathways; not a pharmaceutical intervention.
  • Consult Your Doctor: Always discuss new supplements with your healthcare provider, especially if on anticoagulant therapy.
  • Safe When Used as Directed: Follow dosage instructions for optimal, comfortable results without side effects.

2026 immunizeLABS. All rights reserved.

Contact: sales@immunizelabs.com

Back to blog